These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32896015)

  • 21. Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice.
    Wang R; Yamada T; Arai S; Fukuda K; Taniguchi H; Tanimoto A; Nishiyama A; Takeuchi S; Yamashita K; Ohtsubo K; Matsui J; Onoda N; Hirata E; Taira S; Yano S
    Mol Cancer Ther; 2019 May; 18(5):947-956. PubMed ID: 30926637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
    Mehta A; Zhang L; Boufraqech M; Zhang Y; Patel D; Shen M; Kebebew E
    Endocr Relat Cancer; 2015 Jun; 22(3):319-29. PubMed ID: 25972243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergic Induction of Autophagic Cell Death in Anaplastic Thyroid Carcinoma.
    Wächter S; Knauff F; Roth S; Keber C; Holzer K; Manoharan J; Maurer E; Bartsch DK; Di Fazio P
    Cancer Invest; 2023 Apr; 41(4):405-421. PubMed ID: 36811581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.
    Lin SF; Lin JD; Chou TC; Huang YY; Wong RJ
    PLoS One; 2013; 8(10):e77684. PubMed ID: 24155971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. INHIBITOR OF THE TRANSCRIPTION FACTOR NF-κB, DHMEQ, ENHANCES THE EFFECT OF PACLITAXEL ON CELLS OF ANAPLASTIC THYROID CARCINOMA IN VITRO AND IN VIVO.
    Pushkarev VV; Starenki DV; Pushkarev VM; Kovzun OI; Tronko MD
    Ukr Biochem J; 2015; 87(3):63-74. PubMed ID: 26502701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Aurora-A inhibits tumor progression and sensitizes thyroid carcinoma to Sorafenib by decreasing PFKFB3-mediated glycolysis.
    Jingtai Z; Linfei H; Yuyang Q; Ning K; Xinwei Y; Xin W; Xianhui R; Dongmei H; Weiwei Y; Xiangrui M; Tianze Z; Wei W; Xiangqian Z
    Cell Death Dis; 2023 Mar; 14(3):224. PubMed ID: 36990998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
    Kawamura Y; Saijo K; Imai H; Ishioka C
    Cancer Sci; 2021 Nov; 112(11):4711-4721. PubMed ID: 34328666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Paclitaxel and combination of the drug with radiation therapy in an in vivo model of anaplastic thyroid carcinoma.
    Pushkarev VM; Starenki DV; Saenko VO; Tronko MD; Yamashita S
    Exp Oncol; 2011 Mar; 33(1):24-7. PubMed ID: 21423091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective anti-tumor activity of glutathione-responsive abasic site trapping agent in anaplastic thyroid carcinoma.
    Chai J; Su M; Zhang R; Li N; Jia Y; Zheng W; Tan J; Jia Q; Sun H; Meng Z
    BMC Cancer; 2024 Jul; 24(1):816. PubMed ID: 38977966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
    Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
    Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
    Wang W; Zhou J; Zhao L; Chen S
    Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.
    Copland JA; Marlow LA; Kurakata S; Fujiwara K; Wong AK; Kreinest PA; Williams SF; Haugen BR; Klopper JP; Smallridge RC
    Oncogene; 2006 Apr; 25(16):2304-17. PubMed ID: 16331265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
    Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
    Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nobiletin Alone or in Combination with Cisplatin Decreases the Viability of Anaplastic Thyroid Cancer Cell Lines.
    Sousa DP; Pojo M; Pinto AT; Leite V; Serra AT; Cavaco BM
    Nutr Cancer; 2020; 72(2):352-363. PubMed ID: 31287730
    [No Abstract]   [Full Text] [Related]  

  • 37. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.
    Isham CR; Bossou AR; Negron V; Fisher KE; Kumar R; Marlow L; Lingle WL; Smallridge RC; Sherman EJ; Suman VJ; Copland JA; Bible KC
    Sci Transl Med; 2013 Jan; 5(166):166ra3. PubMed ID: 23283368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2.
    Wang C; Zhang R; Tan J; Meng Z; Zhang Y; Li N; Wang H; Chang J; Wang R
    Oncol Rep; 2020 May; 43(5):1491-1502. PubMed ID: 32323855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
    Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
    Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
    BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.